1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Oncology Center of Excellence Grows Leadership Structure, With A Vacancy Remaining

 
• By Derrick Gingery

A deputy center director position remains open and four new associate director positions were added over the last year.

US FDA's Oncology Center of Excellence celebrated its Third Anniversary on 5 February 2020.
The US FDA Oncology Center of Excellence used a 5 February public workshop to celebrate its third birthday. Not pictured is a cake with balloons that read "Happy 3rd Birthday." • Source: Derrick Gingery

In less than a year, the US Food and Drug Administration’s Oncology Center of Excellence has undergone a significant leadership shake-up with several additions and subtractions from the ranks.

Between March 2019 and January 2020, five existing positions changed hands and another was not filled following a departure. At...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.

More from Agency Leadership